Buy Victoza

Victoza® is indicated for use once a day in adult patients with type 2 diabetes mellitus with diet and exercise to achieve glycemic quality control:

 

- Monotherapy;

 

- Combination therapy with one or more oral hypoglycemic drugs (with metformin, sulfonyl-urea derivatives or thiazolidindions), in patients who have not achieved adequate glycemic control in the previous therapy;

 

- Combined therapy with basal insulin in patients who have not achieved adequate glycemic control on therapy with Victoza® and metformin.

In 1 ml of the drug is contained:

active ingredient: liraglutide 6 mg (one 3 ml syringe-filled handle contains 18 mg of liraglutide);

auxiliary substances: sodium hydrophosphate dihydrate 1.42 mg, propylene glycol 14.0 mg, phenol 5.5 mg, hydrochloric acid/sodium hydroxide q.s., water for injection up to 1 ml.

Victoza® is used once a day at any time, regardless of the meal, and can be injected as a subcutaneous injection into the abdomen, thigh or shoulder.

The place and time of injection can be changed without dose correction. 

Victoza® must not be injected intravenously or intramuscularly.

 

Dose

 

To improve gastrointestinal tolerance, the initial dose of the drug is 0.6 mg per day.

 

After using the medicine for at least one week, the dose should be increased to 1.2 mg.

 

There is evidence that in some cases the efficiency of treatment increases with increasing the dose of the drug from 1.2 mg to 1.8 mg. In order to achieve the best glycemic control of the patient and taking into account the clinical efficiency, the dose of Victosa® can be increased up to 1.8 mg after its use in the dose of 1.2 mg for at least one week.

 

It is not recommended to use the product in a daily dose above 1.8 mg.

 

 

Victoza® can be used in addition to existing metformin therapy or combined therapy with metformin and thiazolidindione. The therapy with metformin and thiazolididine can be continued in the same doses.

 

Victoza® can be added to existing therapy with sulphonylurea derivatives or to combined therapy with metformin and sulphonylurea derivatives. When adding Victosa® to the therapy of sulfonil urea derivatives it is necessary to take into account the reduction of sulfonil urea derivatives dose in order to minimize the risk of unwanted hypoglycemia occurrence.

 

When adding the drug Victoza ® to the therapy of basal insulin should be considered the reduction of insulin dose to minimize the risk of hypoglycemia.

Blood glucose self-control is not required for correction of Victoza® dosage. However, at the beginning of Victoza® therapy in combination with sulphonylurea derivatives or basal insulin, such self-control of blood glucose may be required to correct the dose of sulphonylurea derivatives or basal insulin.

 

 

Missed dose

 

If the dose is missed, Victoza® should be administered as soon as possible within 12 hours of the scheduled dose.

If the skip is more than 12 hours, Victoza® should be administered the next day at the scheduled time.

An additional or increased dose of Victoza® should not be administered the next day to compensate for missed dose.

 

 

Special groups of patients

 

Elderly age (> 65 years): No age-related dose adjustment is required. There is limited experience with the drug in patients aged 75 years and older.

 

 

Patients with liver failure

 

Currently there is limited experience with Victosa® in patients with liver failure, so it is contraindicated for patients with mild, moderate or severe liver failure.

 

 

Patients with renal failure

 

No dose correction is required for patients with mild to moderate renal failure (creatinine clearance 60-90 ml/min and 30-59 ml/min respectively).

There is no experience of the drug application in patients with severe renal insufficiency (creatinine clearance below 30 ml/min). At present, Victoza® use for patients with severe renal impairment, including patients with the terminal stage of renal insufficiency, is contraindicated.

 

 

Children

 

The use of Victoza® for children and adolescents under 18 years of age is contraindicated due to the lack of data on safety and efficiency.

• hypersensitivity to liraglutide or any of the drug's auxiliary substances;

 

• medullary thyroid cancer in the history, including family history;

 

• multiple endocrine neoplasia type 2;

 

• type 1 diabetes mellitus;

 

• diabetic ketoacidosis;

 

The use of Victoza® is contraindicated for the following groups of patients and for the following states/diseases due to lack of data on efficiency and safety:

 

• chronic heart failure, functional class IV (according to the NYHA classification);

 

• inflammatory bowel diseases;

 

• diabetic gastroparesis;

 

• terminal stage of renal failure (Cl creatinine < 15 ml/min);

 

• pregnancy;

 

• lactation period;

 

• under 18 years of age

 

It is not recommended to use in patients with severe liver failure.

 

Be careful:

due to limited experience Victoza® is recommended to be used with caution in patients with thyroid diseases and acute pancreatitis in the history.

The most commonly reported undesired reactions during clinical trials were gastrointestinal abnormalities: nausea and diarrhoea were very common, and vomiting, constipation, abdominal pain and dyspepsia were common. At the beginning of Victoza® therapy, these unwanted gastrointestinal disturbances may occur more frequently; these reactions usually weaken within a few days or weeks as the therapy continues.

 

 

Unwanted reactions are grouped according to the MedDRA organ systems and frequency. The frequency is defined as follows: very often (≥1/10); often (≥1/100 to <1/10); not often (≥1/1000 to <1/100); rarely (≥1/10000 to <1/1000); very rarely (<1/10000).

 

 

Infections and invasions: often - upper respiratory tract infections.

 

Violations of the immune system: rarely - anaphylactic reactions.

 

Metabolism and nutrition disorders: often - hypoglycemia, anorexia, reduced appetite; not often - dehydration.

 

Nervous system disorders: often - headache, dizziness.

 

Heart: often - increase in HP.

 

GIT: very often - nausea, diarrhea; often - vomiting, dyspepsia, upper abdominal pain, constipation, gastritis, flatulence, bloating, GERD, burping; very rarely - pancreatitis (including pancreonecrosis).

 

Biliary tract: not often - cholecystitis, cholecystitis.

 

Skin and subcutaneous tissues: often - a rash, rarely - hives, itching.

 

Kidney and urinary tract: not often - kidney dysfunction, acute renal failure.

 

General disorders and reactions at the injection sites: often - increased fatigue, reactions at the injection sites; not often - malaise.

 

Laboratory methods of investigation: often - increased activity of lipase, amylase.

Symptoms: Typically, patients reported severe nausea, vomiting and diarrhoea, but recovered without residual effects. None of the patients had severe hypoglycemia.

 

Treatment: in case of overdose of Victoza® preparation, appropriate symptomatic therapy is recommended.

A retrospective analysis of the database of patients with type 2 diabetes mellitus showed that the use of Victosa® in a dose of 1.8 mg during 26 weeks in patients with initial HbA1c < 8.5%, shorter duration of the disease (< 4.9 years) and previous therapy with one sugar-reducing drug or diet more often leads to a decrease in HbA1c < 7% without weight gain and hypoglycemia. Meta-analysis data studies were presented at the 48th Annual Congress of the European Association for the Study of Diabetes (EASD) in Berlin, Germany.

 

"Based on our experience with the clinical application of liraglutide, we know that the drug is very effective in reducing blood glucose levels and provides the patient with the added benefit of weight loss," said Dr. Vanita Aroda, research scientist at MedStar Medical Research Institute (Hyattsville, USA).

 

These studies have shown the following:

 

• On average, 34% of patients who used liraglutide in the dose of 1.8 mg reached the specified composite index;

 

• at the same time, 46% of patients with baseline HbA1c < 8.5% achieved the composite index;

 

• 56% of patients who had used a single sugar reducing agent or diet therapy before prescribing liraglutide achieved a composite index, while among patients who had initially used combined sugar reducing therapy only 36% achieved a similar total index (p < 0.0001);

 

• In a gender analysis of patients it was found that 74% of female patients with baseline HbA1c < 8.5% who had used one sugar-reducing drug or diet therapy and had a disease duration of < 4.9 years reached a composite index

Therapy, including taking the drug for 3 months,
is effective in terms of weight loss and
adipose tissue in the body and, in addition, leads to improved carbohydrate and lipid metabolism.

 

Treatment in combinations with image enhancement activities
of life, is well tolerated, safe, efficient in terms of impact on key
pathophysiological basis of obesity - abdominal obesity and insulin resistance, which together contribute to reducing the overall cardiometabolic risk and improve the quality and prognosis of life in
of the patients.

 

 

52-week monotherapy with Victoza® was associated with a steady decrease in body weight.

 

The decrease of body weight in patients receiving Victosa® in combination with metformin was also observed after basal insulin addition.

 

The greatest decrease in body weight was observed in patients who had increased BMI at the initial point of study.

 

Weight loss was observed in all patients treated with Victoza®.

 

Victoza® monotherapy during 52 weeks caused the average waist volume reduction by 3-3.6 cm.

 

Victoza® in combination therapy with metformin decreased visceral fat volume by 13-17%.

• Victoza was originally intended to reduce sugar levels in case of diabetes. Saxenda was designed for weight loss.

 

• One pack of Victoza - 2 syringes, Saxenda - 5 syringes.

 

More information about Saxenda on the link.

At 2-8 °C.

In the fridge, but not near the freezer.

Store the used syringe pen with the product at a temperature no higher than 30 °C or in the refrigerator (at 2 °C to 8 °C).

Do not freeze.

Use for 1 month. Cover the pen syringe with a cap to protect against light.

 

Keep it out of the reach of children.

 

 

Shelf life: 30 months.

Full description (PDF).

You can buy Victoza from our website absolutely legally.

Delivery is carried out to all countries in the world, which do not have an official ban on receiving and sending mail (mainly island countries).

We guarantee that you will receive your parcel with Victoza without any problems at customs (we have our own delivery channels to countries with strict customs).

We guarantee a refund if your package has not been delivered to you for any reason, according to PayPal protection policy.

Due to Quarantine, delivery time may increase slightly, but still delivery remains within reasonable limits and does not exceed the delivery time during Christmas sales.

There is no prescription required!

You can legally buy Victoza on our website without prescription!